MedTrace Logo

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects

NCT07269756 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-15

No results posted yet for this study

Summary

This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.

Conditions

Interventions

DRUG

HRS-7535 Tablets

HRS-7535 tablet.

DRUG

Paracetamol Tablets

Paracetamol tablet.

DRUG

Digoxin Tablets

Digoxin tablet.

DRUG

Rosuvastatin Calcium Tablets

Rosuvastatin Calcium tablet.

DRUG

Omeprazole Enteric-coated Capsules

Omeprazole Enteric-coated capsule.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2026-03-08
Completion
2026-03-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07269756 on ClinicalTrials.gov